SequelSEC

Tyra Biosciences, Inc. TYRA

Pharmaceutical Preparations · CIK 0001863127 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$132.76M
Fiscal year ended 2025-12-31
Free cash flow
-$95.28M
Fiscal year ended 2025-12-31

Tyra Biosciences, Inc. (TYRA) reported net income of -$119.95M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Tyra Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Tyra Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$132.76M-$104.18M-$79.94M-$58.93M-$26.29M-$9.30M
Net income-$119.95M-$86.48M-$69.13M-$55.32M-$26.29M-$9.34M
Research & development$102.93M$80.08M$62.52M$43.01M$20.64M$7.20M
Weighted-average diluted sharesshares 59.60Mshares 57.22Mshares 42.70Mshares 41.88Mshares 13.78MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$2.00K$1.00K$1.00K
Diluted EPS$-2.01$-1.51$-1.62$-1.32$-1.91Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$29.83M$24.10M$17.43M$15.92M$5.65M$2.09M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Tyra Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$77.39M$91.97M$58.01M$251.21M$302.18M$15.22M
Total assets$282.61M$363.56M$225.86M$266.18M$306.70M$16.01M
Current assets$265.45M$347.46M$211.67M$257.29M$304.06M$15.28M
Total liabilities$23.43M$20.41M$21.60M$8.35M$4.96M$2.00M
Current liabilities$18.09M$14.59M$15.33M$5.70M$3.62M$1.86M
Total equity incl. NCI$259.18M$343.15M$204.26M$257.83M$301.74M-$13.64M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$27.65M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.18M$590.00K$4.66M$1.14M$599.00K$664.00K

Cash flow

Tyra Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$95.14M-$69.77M-$50.14M-$50.28M-$23.74M-$7.76M
Capital expenditures$141.00K$664.00K$770.00K$559.00K$661.00K$312.00K
Investing cash flow$72.46M-$98.40M-$144.60M-$559.00K-$645.00K-$312.00K
Financing cash flow$8.10M$202.14M$1.54M$632.00K$311.35M$23.43M
Net change in cash-$14.58M$33.96M-$193.21M-$50.21M$286.96M$15.36M
Stock-based compensation$28.01M$22.80M$13.52M$10.59M$2.89M$439.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$546.00K$519.00K$357.00K$296.00K$140.00K$47.00K

Derived

Tyra Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$95.28M-$70.44M-$50.91M-$50.84M-$24.41M-$8.08M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio14.67x23.81x13.80x45.13x84.09x8.22x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TYRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.